Gilead Sciences, Inc. (Nasdaq: GILD) announces it has entered into a definitive agreement to acquire Ouro Medicines, a privately held biotechnology company focused on developing T cell engager therapies for autoimmune diseases. The acquisition adds OM336 (gamgertamig), a clinical‑stage BCMAxCD3 T cell engager, to Gilead’s growing inflammation portfolio. OM336 is designed to enable rapid and deep B cell depletion following a limited subcutaneously administered treatment course. Under the terms of the agreement Gilead will acquire all of the outstanding equity of Ouro Medicines for a total of $1,675 million in upfront cash consideration, subject to customary adjustments, which is payable at closing, and up to $500 million in contingent milestone payments.
Read the full article: Gilead Sciences to Acquire Ouro Medicines to Advance First in Class T Cell Engager Program for Autoimmune Diseases //
Source: https://www.businesswire.com/news/home/20260323998270/en/Gilead-Sciences-to-Acquire-Ouro-Medicines-to-Advance-First-in-Class-T-Cell-Engager-Program-for-Autoimmune-Diseases